- Atlas
- Medicine & Health
- Pharmaceutics
Pharmaceutics
Pharmaceutics is the branch of pharmacy that turns a drug substance into a medicine a patient can actually take.
11 frameworks, from 150 to today · Pharmacy · Medicine & Health
- Galenical compounding 150-1850
- Pharmacopoeia 1618-Present
- Dosage-Form Design 1840-Present
- Industrial tablet and capsule manufacture 1880-Present
- Modified-release dosage 1950-Present
- Biopharmaceutics 1955-Present
- Drug delivery 1970-Present
- Computational and predictive formulation 1990-Present
- Biopharmaceutics Classification System 1995-Present
- Quality by Design 2002-Present
- Continuous manufacturing 2010-Present
Overview
Pharmaceutics is the branch of pharmacy that turns a drug substance into a medicine a patient can actually take1. A pure chemical, however potent, is rarely usable as it comes: it may taste vile, dissolve too slowly or too fast, irritate the stomach, degrade in storage, or fail to reach the tissue where it is needed1. Pharmaceutics is the craft and science of the dosage form—the tablet, capsule, syrup, ointment, injection, patch, or inhaler—and of everything that determines whether that form delivers the drug reliably and safely1. Its history is the story of how making medicines moved from the apothecary's mortar to the pharmaceutical factory and then to the engineered delivery system, and of how the field learned to predict what a formulation would do inside the body rather than only describe it on the shelf.
Compounding from the materia medica
For most of history, the medicine was made at the moment it was prescribed. The apothecary worked from the materia medica—the accumulated catalogue of crude drugs of plant, animal, and mineral origin—and prepared galenicals: extracts, tinctures, infusions, decoctions, syrups, pills, and plasters named for Galen, the second-century physician whose authority shaped pharmacy for centuries. The skills were extraction and combination: choosing the solvent, controlling the heat, masking a bitter taste, and rolling a pill that would hold together.
This was a craft of recipes and received authority, and its weakness was inconsistency. The same tincture made by two apothecaries could differ in strength. The response was pharmacopoeial standardization: official books, beginning with city pharmacopoeias in the Renaissance and early modern period, that fixed recipes, strengths, and tests so that a "tincture of opium" meant the same thing in different shops. The Pharmacopoeia Londinensis of 1618 and later national pharmacopoeias were instruments of this kind2. Standardization did not yet explain why a preparation behaved as it did; it simply made preparations reproducible.
The rise of industrial manufacture
The nineteenth century broke the apothecary's monopoly on making medicines. The isolation of active principles—morphine from opium by Friedrich Sertürner around 1804 is the landmark—meant that a drug could be a single purified substance rather than a variable plant extract. Once the active ingredient was a chemical, its formulation became a manufacturing problem: how to compress it into a tablet of uniform dose, how to coat it, how to keep it stable.
The compressed tablet, developed commercially in the later nineteenth century (the British firm Burroughs Wellcome was among the pioneers of the modern compressed tablet in the 1880s), became the emblem of industrial pharmacy. Mass production demanded new questions. A tablet is not just drug: it is drug plus excipients—inert ingredients that give it bulk, bind it, help it disintegrate, lubricate it during pressing, and preserve it34. The engineering of excipients and tablets became a discipline of its own, concerned with flow, compression, hardness, friability, and disintegration. The gelatin capsule, patented in the mid-nineteenth century, offered another route to a uniform, tasteless dose.
Biopharmaceutics: asking what happens after the swallow
Through the mid-twentieth century, pharmaceutics largely judged a dosage form by its physical properties—does the tablet crumble in water, does the syrup pour. The decisive shift came with biopharmaceutics, the study of how the dosage form governs the rate and extent of drug absorption into the body. The key measure is bioavailability: the fraction of a dose that reaches the bloodstream unchanged, and how fast.
The turning point was the recognition that two products containing the same drug could behave differently in patients. Studies of drug absorption in the 1950s and 1960s, and the thalidomide-era scrutiny of drug safety that followed, made formulation a matter of therapeutic consequence rather than manufacturing convenience. If a tablet dissolved too slowly, the patient might absorb too little; if it released too fast, blood levels could spike. Bioequivalence—the demonstration that two formulations deliver drug comparably—became a regulatory requirement, and dissolution testing in the laboratory became a surrogate for what happened in the gut.
Designing release
Once absorption could be measured, it could be controlled. Modified-release systems were built to change when and how fast a drug appears in the body: delayed-release coatings that survive the stomach, extended-release matrices that meter drug out over hours, and eventually controlled-release systems engineered to hold blood levels steady. The oral osmotic pump (the OROS system, developed from the 1970s) is a classic example: a tablet with a laser-drilled hole that releases drug at a near-constant rate driven by osmotic pressure. These systems solved a real problem—drugs that had to be taken several times a day, with peaks and troughs that caused side effects or lost effect—by making the dosage form itself a timing device.
The same logic broadened into drug delivery systems: transdermal patches that deliver through the skin over days, implants and depot injections that release for weeks or months, liposomes and nanoparticles that carry drug to particular tissues, and inhalers that deposit drug in the lung. Here pharmaceutics merged with materials science and polymer chemistry, and the question shifted from "how do we make a stable tablet" to "how do we engineer a device that talks to the body."
Predicting behaviour: the BCS and computational formulation
A parallel strand made formulation predictive. The Biopharmaceutics Classification System (BCS), set out by Gordon Amidon and colleagues in the 1990s, sorted drugs by two properties—aqueous solubility and intestinal permeability—into four classes. The insight was that these two variables largely explain whether a drug will be well absorbed and whether its formulation is sensitive to dissolution rate. The BCS gave regulators and formulators a rational basis for waiving some bioequivalence studies and for deciding which formulation problems actually matter.
Computational and predictive formulation grew alongside it: models of dissolution, of powder flow, of pharmacokinetics, and later simulation of manufacturing processes. The aim was to replace trial-and-error formulation with design based on measurable properties.
Quality by design and continuous manufacturing
The most recent turning point concerns how quality itself is assured. The traditional model tested a finished batch and rejected it if it failed—quality by inspection. Quality by Design (QbD), pressed by regulators including the U.S. Food and Drug Administration in the 2000s, instead builds quality into the process: identify the critical quality attributes of the product, understand how process parameters affect them, and design a control space within which the product is reliably good. It descends directly from the statistical process-control tradition and from the recognition that a tablet's behaviour is the product of many interacting variables.
Continuous manufacturing carries the same logic further: instead of making a drug in discrete batches, raw materials flow through an integrated line—blending, granulation, tableting—in a continuous stream, monitored in real time5. It promises consistency, flexibility, and smaller footprints, and it depends on the sensors and models that predictive formulation made possible.
Where pharmaceutics stands now
Today's pharmaceutics works across all these layers at once. A formulator may use the BCS to decide whether a solubility problem needs solving, apply QbD to define a design space, engineer a modified-release matrix or a nanoparticle carrier, and run the product on a continuous line with in-process monitoring. The open questions are substantial: predicting in vivo behaviour from in vitro tests remains imperfect; biologics—proteins and nucleic acids—pose stability and delivery problems that classical small-molecule formulation did not; and personalized dosing, including 3D-printed dosage forms, challenges the batch-manufacturing model that shaped the field. The through-line from the apothecary's mortar is intact: pharmaceutics is still the discipline that decides what the patient actually receives, and increasingly it can say in advance what that form will do once swallowed, injected, or inhaled.
References
- Pharmaceutics (introduction, Description, History), Wikipedia
- British Pharmacopoeia (History), Wikipedia
- Dosage form, Wikipedia
- Excipient, Wikipedia
- Pharmaceutical manufacturing (Powder feeding in continuous manufacturing), Wikipedia
The frameworks of Pharmaceutics
Each framework is a way of working the field has used: when it held, and the question it answers.
- 150-1850
- 1618-Present
- 1840-Present
- 1880-Present
Industrial tablet and capsule manufacture
How are tablets made uniformly in large numbers?
- 1950-Present
- 1955-Present
- 1970-Present
- 1990-Present
Computational and predictive formulation
Can we predict what a formulation will do?
- 1995-Present
Biopharmaceutics Classification System
Which drug properties decide absorption?
- 2002-Present
- 2010-Present
How the ideas connect
Each arrow runs from an earlier idea to the later one it shaped. The list below says what passed between them.
Pharmacopoeia grew out of Galenical compounding
Pharmacopoeias grew directly out of galenical compounding: they fixed the recipes, strengths, and tests for the extracts, tinctures, and pills that apothecaries made, so that a preparation would be reproducible across shops. The Pharmacopoeia Londinensis of 1618 is the landmark codification of this craft.
Carried by Pharmacopoeia Londinensis (1618).
Industrial tablet and capsule manufacture grew out of Dosage-Form Design
Industrial tablet and capsule manufacture grew directly out of dosage-form design: once the dose was a defined physical object, the problems of compressing it uniformly, coating it, and keeping it stable became manufacturing engineering. The compressed tablet pioneered commercially by Burroughs Wellcome in the 1880s is the emblem of this transition.
Carried by Burroughs Wellcome.
Modified-release dosage influenced by Biopharmaceutics
Biopharmaceutics supplied the measurement—bioavailability and dissolution rate—that made release controllable: once absorption could be quantified, formulators could design coatings and matrices to change when and how fast drug appeared in the blood. The oral osmotic pump and extended-release matrix are engineering answers to questions biopharmaceutics posed.
Biopharmaceutics Classification System grew out of Biopharmaceutics
The Biopharmaceutics Classification System is a direct refinement of biopharmaceutics: Gordon Amidon and colleagues sorted drugs by aqueous solubility and intestinal permeability, the two variables biopharmaceutics had identified as governing absorption, into four classes. It turned the field's empirical findings into a predictive regulatory tool.
Carried by Gordon Amidon.
Continuous manufacturing grew out of Quality by Design
Continuous manufacturing carries Quality by Design's logic further: instead of assuring quality within a batch's design space, raw materials flow through an integrated line monitored in real time, so quality is controlled continuously rather than batch by batch. It depends on the sensors and process models QbD made central.
Dosage-Form Design influenced by Galenical compounding
The compounding tradition supplied the basic operations and questions—extraction, combination, masking taste, making a dose that holds together—that dosage-form design took up and reworked once the active ingredient became a purified chemical. The apothecary's pill-rolling and pill-coating became the tablet and capsule problems of the industrial era.
Dosage-Form Design influenced by Pharmacopoeia
Pharmacopoeial standardization established the expectation of uniform strength and reproducible preparations, a requirement that dosage-form design inherited when manufacture moved from the shop to the factory. Official monographs and tests became the benchmark against which industrial tablets and capsules were specified.
Modified-release dosage influenced by Industrial tablet and capsule manufacture
Industrial tablet manufacture provided the platform—compressed matrices, coatings, and capsule shells—on which modified-release systems were later built, and its excipient engineering supplied the polymers and coating techniques that made controlled release possible. The shift from making a tablet that disintegrates to one that meters drug out over hours presupposed the industrial tablet.
Biopharmaceutics influenced by Industrial tablet and capsule manufacture
Mass-produced tablets and capsules created the problem biopharmaceutics was formed to answer: products with the same drug could behave differently in patients, so the physical properties of the industrial dosage form had to be related to absorption. Dissolution testing and bioavailability studies arose to explain why factory-made tablets of identical composition performed unequally.
Quality by Design reacted against Industrial tablet and capsule manufacture
Quality by Design arose as a rejection of the batch-inspection model that industrial tablet manufacture had established: instead of testing a finished batch and rejecting it, QbD builds quality into the process by identifying critical quality attributes and control spaces. The FDA pressed this shift in the 2000s against the traditional end-product testing of factory pharmacy.
Carried by U.S. Food and Drug Administration.
Drug delivery grew out of Modified-release dosage
Drug delivery systems grew out of modified-release dosage: the timing devices built for oral tablets—osmotic pumps, matrices, delayed coatings—were generalized into patches, implants, and carriers that release over days or weeks and to particular tissues. The OROS system is a direct ancestor of this broadening.
Carried by OROS.
Drug delivery grew out of Biopharmaceutics
Drug delivery broadened biopharmaceutics from measuring absorption to engineering it: the same bioavailability questions were extended from the gut to the skin, lung, and implanted depot, and from timing release to targeting tissue. Transdermal patches, liposomes, and inhalers carry the biopharmaceutical logic into device design.
Computational and predictive formulation influenced by Biopharmaceutics
Computational and predictive formulation took up the biopharmaceutical aim of predicting in vivo behaviour, building models of dissolution and pharmacokinetics to replace trial-and-error with design from measurable properties. The bioavailability questions of the 1950s and 1960s became the simulation targets of the 1990s.
Quality by Design influenced by Computational and predictive formulation
Quality by Design depends on the process understanding and models that computational formulation developed: identifying how process parameters affect critical quality attributes requires the simulation and statistical process-control tools of predictive formulation. QbD's design space is a modelled space.
Continuous manufacturing influenced by Computational and predictive formulation
Continuous manufacturing relies on the real-time sensors and predictive models that computational formulation produced, using them to monitor blending, granulation, and tableting in process rather than testing a finished batch. The in-process monitoring of a continuous line is applied predictive formulation.
Computational and predictive formulation influenced by Biopharmaceutics Classification System
The BCS gave computational formulation a rational classification to build on: solubility and permeability classes became inputs for models deciding which formulation problems matter and for predicting absorption without a clinical study. Regulatory waivers based on BCS made predictive formulation a practical tool.
Carried by Gordon Amidon.
Beyond the field
Where Pharmaceutics's ideas came from in other fields, and what they led to there: the strongest 12 of 44 links.
Galenical compounding led to Compounding practice in Pharmacy
Compounding practice is the continuation and extension of Galenical compounding, retaining its operations of infusion, decoction, tincture and electuary while adding new classes of preparation. The later practice grew directly out of the Galenic repertoire.
Pharmacopoeia led to Pharmacopoeial Standardization in Pharmacy Practice
Pharmacopoeial standardization is the regulatory and analytical programme that grew out of the pharmacopoeia: the compendium's monographs became the basis for fixed standards of identity, purity and strength. The London Pharmacopoeia of 1618 is the early carrier of this move from recipe book to standard.
Carried by Pharmacopoeia Londinensis (1618).
Modified-release dosage influenced by Pharmacokinetics in Pharmacology
Pharmacokinetics gave modified-release dosage its quantitative target: maintaining plasma concentrations within a therapeutic window. Release-rate design was calculated from pharmacokinetic parameters such as clearance and half-life.
Modified-release dosage influenced by Pharmacokinetics in Pharmacology
Pharmacokinetics provided the concepts of absorption rate, half-life and plasma level that modified-release design set out to control. Sustained-release formulations were designed to flatten the concentration-time curve predicted by pharmacokinetic models.
Modified-release dosage influenced by Pharmacokinetics in Clinical Pharmacology
Modified-release dosage was built on pharmacokinetics: plasma concentration-time curves and half-life data gave the rationale for sustaining drug levels. The design of sustained-release forms was driven by pharmacokinetic measurement of absorption and elimination.
Modified-release dosage influenced Long-acting reversible contraceptives in Contraception And Family Planning
Long-acting reversible contraceptives depend on modified-release dosage technology, which sustains drug levels over months or years from implants and intrauterine systems. Pharmaceutical controlled-release methods were taken up and applied to steroid contraception.
Biopharmaceutics grew out of Pharmacokinetics in Pharmacology
Biopharmaceutics grew directly out of pharmacokinetics: measuring drug in blood after dosing revealed that the dosage form governs absorption. The rate and extent of absorption became the object of study, splitting biopharmaceutics off from pharmacokinetics proper.
Biopharmaceutics grew out of Pharmacokinetics in Pharmacology
Biopharmaceutics is a branch grown from pharmacokinetics, taking its plasma-level methods and applying them to the influence of formulation on absorption. The pharmacokinetic framework supplied the measurements that defined bioavailability.
Biopharmaceutics grew out of Pharmacokinetics in Clinical Pharmacology
Biopharmaceutics grew out of pharmacokinetics as applied in clinical pharmacology, where plasma concentration measurements after dosing exposed formulation effects on absorption. The clinical pharmacokinetic methods were the direct source of biopharmaceutic study.
Drug delivery grew out of Pharmaceutics in Pharmacy
Drug delivery emerged as a branch of pharmaceutics, taking over its concern with dosage form design and extending it to controlled and targeted release. The formulation science of pharmaceutics is the direct parent discipline.
Computational and predictive formulation grew out of Pharmaceutics in Pharmacy
Computational and predictive formulation is a branch of pharmaceutics, applying its formulation questions to simulation and modelling rather than bench experiment.
Biopharmaceutics Classification System influenced by Pharmacokinetics in Pharmacology
The BCS rests on pharmacokinetic understanding of dissolution and absorption as rate-limiting steps; Amidon and colleagues built the classification directly on pharmacokinetic concepts of permeability and absorption rate.
Carried by Gordon Amidon.

Pharmaceutics is a planet in Nousfarer
Its city has a tower for each of these 11 frameworks. Land, walk in, and climb one concept at a time.
Land on PharmaceuticsRelated fields
Fields its ideas are linked to
- Pharmacy 13 links
- Pharmacology 5 links
- Quality Engineering 4 links
- Clinical Pharmacology 4 links
- Medicinal Chemistry 3 links
- Drug Discovery 3 links
- Pharmacometrics 2 links
- Pharmacy Practice 2 links
- Aquatic Nutrition 1 link
- Chemistry 1 link
- Gastroenterology And Hepatology 1 link
- Pharmacokinetics 1 link